Neurite outgrowth inhibitor (Nogo-A) (Nogo-A)

Neurite outgrowth inhibitor (Nogo-A) is a high-molecular-weight transmembrane protein belonging to the reticulon family (RTN4) that serves as a potent inhibitor of axonal regeneration in the adult central nervous system (CNS) [5, 6]. It is primarily expressed by oligodendrocytes and is localized to the myelin sheath, where it prevents the repair of neural circuits following injury or disease [6, 8]. Nogo-A functions by binding to the Nogo receptor 1 (NgR1), which initiates a signaling cascade involving the RhoA GTPase, ultimately leading to growth cone collapse and the cessation of neurite extension [8]. Because of its central role in limiting CNS plasticity, Nogo-A is a major therapeutic target for conditions such as spinal cord injury, amyotrophic lateral sclerosis (ALS), and multiple sclerosis [5, 6]. Therapeutic strategies include the use of monoclonal antibodies, such as ozanezumab, and decoy receptors like AXER-204 to neutralize Nogo-A activity and promote functional recovery [5, 8]. Although "Neurite" is a general anatomical term for neuronal projections, in the context of drug development, it most frequently refers to the molecular pathways governed by Nogo-A and its associated inhibitors [6, 9].

Other names

RTN4Reticulon-4NogoNogo-AASYNSPNSP-CLRTN-XMyelin-associated neurite outgrowth inhibitor

Neutralization of Nogo-A or its receptor (NgR1) using monoclonal antibodies or decoy receptors to block inhibitory signaling and promote axonal regrowth and neural plasticity.